Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Marcus Anthony Urey, MD, University of California, San Diego, CA, comments on the use of RNA interference (RNAi) therapy in patients with hereditary transthyretin-mediated (hATTR) amyloidosis who have both cardiac and neurological involvement. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.
Disclosures
Consultancy: Alnylam, Akcea, BridgeBio
Honoraria: Pfizer
Research support: Ionis
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.